Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deuruxolitinib - Sun Pharmaceutical Industries

Next Previous
Drug Profile

Deuruxolitinib - Sun Pharmaceutical Industries

Alternative Names: C-21543 phosphate; CTP-543; CTP-543 phosphate; D8- ruxolitinib phosphate; D8-ruxolitinib; Deuruxolitinib phosphate; Deuterated ruxolitinib; Deuterium ruxolitinib analogue; LEQSELVI; Ruxolitinib deuterated - Concert Pharmaceuticals

Latest Information Update: 18 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Concert Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Cyclopentanes; Nitriles; Organic deuterium compounds; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alopecia areata

Most Recent Events

  • 10 Mar 2026 Preregistration for Alopecia areata in United Kingdom (PO) before March 2026
  • 10 Mar 2026 Registered for Alopecia areata in United Kingdom (PO) via International Recognition Procedure
  • 26 Feb 2026 Preregistration for Alopecia areata in European Union (PO) before February 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top